JP2010514409A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514409A5 JP2010514409A5 JP2009515770A JP2009515770A JP2010514409A5 JP 2010514409 A5 JP2010514409 A5 JP 2010514409A5 JP 2009515770 A JP2009515770 A JP 2009515770A JP 2009515770 A JP2009515770 A JP 2009515770A JP 2010514409 A5 JP2010514409 A5 JP 2010514409A5
- Authority
- JP
- Japan
- Prior art keywords
- cytokine
- agent
- tumor
- apoptotic
- expressing tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 18
- 239000003795 chemical substances by application Substances 0.000 claims 13
- 102000004388 Interleukin-4 Human genes 0.000 claims 6
- 108090000978 Interleukin-4 Proteins 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 230000002424 anti-apoptotic Effects 0.000 claims 5
- 102000004965 antibodies Human genes 0.000 claims 5
- 108090001123 antibodies Proteins 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 238000001514 detection method Methods 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 230000000861 pro-apoptotic Effects 0.000 claims 5
- 210000004881 tumor cells Anatomy 0.000 claims 5
- 230000003472 neutralizing Effects 0.000 claims 4
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 3
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 3
- 210000004027 cells Anatomy 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 210000000481 Breast Anatomy 0.000 claims 2
- 210000001072 Colon Anatomy 0.000 claims 2
- 210000002784 Stomach Anatomy 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000038129 antigens Human genes 0.000 claims 2
- 108091007172 antigens Proteins 0.000 claims 2
- 230000027455 binding Effects 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 claims 1
- 206010059512 Apoptosis Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 229960004562 Carboplatin Drugs 0.000 claims 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000003915 DNA Topoisomerases Human genes 0.000 claims 1
- 108090000323 DNA Topoisomerases Proteins 0.000 claims 1
- 230000000970 DNA cross-linking Effects 0.000 claims 1
- 102100003082 FASLG Human genes 0.000 claims 1
- 108010039471 Fas Ligand Protein Proteins 0.000 claims 1
- 229940088597 Hormone Drugs 0.000 claims 1
- 210000004408 Hybridomas Anatomy 0.000 claims 1
- 210000003734 Kidney Anatomy 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- 210000004072 Lung Anatomy 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108020004999 Messenger RNA Proteins 0.000 claims 1
- 210000000496 Pancreas Anatomy 0.000 claims 1
- 210000002307 Prostate Anatomy 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 210000001685 Thyroid Gland Anatomy 0.000 claims 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 claims 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims 1
- 210000003932 Urinary Bladder Anatomy 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 230000003042 antagnostic Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000000973 chemotherapeutic Effects 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 239000003431 cross linking reagent Substances 0.000 claims 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 1
- 238000006062 fragmentation reaction Methods 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 239000003667 hormone antagonist Substances 0.000 claims 1
- 230000000984 immunochemical Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000002687 intercalation Effects 0.000 claims 1
- 238000009830 intercalation Methods 0.000 claims 1
- 230000003902 lesions Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 229920002106 messenger RNA Polymers 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 238000007899 nucleic acid hybridization Methods 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 230000001737 promoting Effects 0.000 claims 1
- 239000000007 protein synthesis inhibitor Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Claims (15)
- (a)腫瘍細胞を含有する充実性腫瘍から試料を提供する工程、
(b)前記腫瘍細胞中の少なくとも1の抗アポトーシス性サイトカインの発現を決定する工程、及び
(c)前記充実性腫瘍を非サイトカイン発現腫瘍またはサイトカイン発現腫瘍に分類する工程
を含む、癌の種類を診断するための方法。 - 抗アポトーシス性サイトカインがIL−4及び/又はIL−10、有利にはIL−4である、請求項1記載の方法。
- 前記充実性腫瘍が、
(a)IL−4発現腫瘍またはIL−4非発現腫瘍、
(b)IL−10発現腫瘍又はIL−10非発現腫瘍、及び/又は
(c)IL−4及びIL−10発現腫瘍又は非IL−4及び非IL−10発現腫瘍に分類される、請求項1又は2記載の方法。 - 充実性腫瘍が上皮腫瘍であり、有利には甲状腺、胸、前立腺、膀胱、結腸、胃、膵臓、腎臓、肝臓及び肺の癌の群から選択され、最も有利には、結腸、胃、胸、肺、膀胱又は前立腺の癌である、請求項1から3までのいずれか1項記載の方法。
- 腫瘍細胞が、プライマリーな腫瘍細胞及び/又は癌胚細胞である、請求項1から4までのいずれか1項記載の方法。
- 腫瘍細胞中での抗アポトーシス性サイトカイン発現の検出が、タンパク質レベル及び/又は核酸レベルでの検出、有利には抗アポトーシス性サイトカインの検出であって有利には免疫化学及び/又は質量分析方法を用いた検出を含むタンパク質レベルでの検出、又は核酸ハイブリダイゼーション及び場合により増幅方法、有利にはRT−PCR方法を用いた抗アポトーシス性サイトカインmRNA発現レベルの決定を含む核酸レベルでの決定を含む、請求項1から5までのいずれか1項記載の方法。
- (d)少なくとも1種の化学療法剤又はアポトーシス促進剤に対する、発現されたサイトカイン及び/又はそのレセプターのアンタゴニストの存在及び/又は非存在中での、サイトカイン発現腫瘍の細胞の感受性を決定する工程、及び
(e)場合により、癌の種類に特異的な処理を選択する工程
を更に含み、
有利には(d)工程において、サイトカイン発現腫瘍の細胞が感受性である化学療法剤又はアポトーシス促進剤が決定され、かつ/又は
(e)工程においてサイトカイン中和剤及び化学療法剤又はアポトーシス促進剤の組み合わせの投与を含む処理が選択される、請求項1から6までのいずれか1項記載の方法。 - (a)化学療法剤が、代謝拮抗剤、DNA断片化剤、DNA架橋剤、インターカレーション剤、タンパク質合成阻害剤、トポイソメラーゼI及びII阻害剤、微小管指向した剤、キナーゼ阻害剤、ホルモン及びホルモンアンタゴニストから選択され、有利には化学療法剤が、シスプラチン、カルボプラチン及びオキサリプラチンから選択され、かつ/又は(b)アポトーシス促進剤が、TRAIL及びCD95リガンドから選択される、請求項7記載の方法。
- サイトカイン中和剤が、抗体、有利には抗IL−4抗体及び/又は抗IL−10抗体又はその抗原結合断片及び溶解性のIL−4レセプターポリペプチド又は融合ポリペプチドから選択され、最も有利には抗IL−4抗体はハイブリドーマ細胞ECACC 93100620又はその抗原結合断片に由来する抗体である、請求項7又は8記載の方法。
- (i)少なくとも1種のサイトカイン中和剤及び
(ii)少なくとも1種の化学療法剤又はアポトーシス促進剤
の組み合わせの、(a)微小残存病変、(b)サイトカイン発現腫瘍として分類される癌の種類、又は(c)手術及び/又は放射線療法との組み合わせにおける、サイトカイン発現腫瘍として分類される癌の種類の治療のための医薬品の製造のための使用。 - 医薬品が、手術及び/又は放射線療法との、同時の、別個の又は逐次の組み合わせ療法のためである、請求項10(c)記載の使用。
- (i)少なくとも1種のサイトカイン中和剤及び
(ii)少なくとも1種の化学療法剤又はアポトーシス促進剤
の組み合わせの、サイトカイン発現腫瘍の治療のための医薬品の製造のためであって、
(a)(i)及び(ii)の投与が同時に開始されるか又は
(b)(i)及び(ii)の投与が段階的に開始される使用。 - (i)の投与の開始が、(ii)の≧1週間前であるか、又は、(ii)の投与の開始が、(i)の≧1週間前である、請求項12(b)記載の使用。
- C末端で短縮された細胞外IL−4レセプタードメインを含有する、有利には融合ポリペプチドである溶解性のIL−4レセプターポリペプチド。
- 請求項14記載のポリペプチドをコードする核酸分子。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06012754 | 2006-06-21 | ||
PCT/EP2007/005480 WO2007147600A2 (en) | 2006-06-21 | 2007-06-21 | Differential il-4 and/or il-10 cytokine expression in human cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010514409A JP2010514409A (ja) | 2010-05-06 |
JP2010514409A5 true JP2010514409A5 (ja) | 2010-06-17 |
Family
ID=38359749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009515770A Pending JP2010514409A (ja) | 2006-06-21 | 2007-06-21 | ヒトの癌における鑑別式サイトカイン発現 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20090324616A1 (ja) |
EP (1) | EP2041576B1 (ja) |
JP (1) | JP2010514409A (ja) |
CN (1) | CN101529253A (ja) |
AT (1) | ATE520032T1 (ja) |
AU (1) | AU2007263265A1 (ja) |
BR (1) | BRPI0713484A2 (ja) |
CA (1) | CA2656379A1 (ja) |
DK (1) | DK2041576T3 (ja) |
ES (1) | ES2371287T3 (ja) |
RU (1) | RU2009101783A (ja) |
WO (1) | WO2007147600A2 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100297110A1 (en) * | 2006-03-22 | 2010-11-25 | Apogenix Gmbh | Antibody specific for human il-4 for the treatment of cancer |
EP2049147A2 (en) * | 2006-07-06 | 2009-04-22 | Apogenix GmbH | Human il-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy |
DK2875045T3 (en) * | 2012-07-18 | 2018-07-02 | Apogenix Ag | COMPOSITION comprising a mixture of CD95-FC ISOFORMs |
US11299528B2 (en) | 2014-03-11 | 2022-04-12 | D&D Pharmatech Inc. | Long acting TRAIL receptor agonists for treatment of autoimmune diseases |
SG11201703326SA (en) * | 2014-10-24 | 2017-05-30 | Aladar Szalay | Combination immunotherapy approach for treatment of cancer |
MX2018001755A (es) | 2015-08-11 | 2018-08-01 | Stemimmune Incorporated | Vacuna contra viruela para tratamiento del cancer. |
CN108601819B (zh) | 2015-12-17 | 2022-03-15 | 约翰霍普金斯大学 | 用死亡受体激动剂改善系统性硬化症 |
KR102508650B1 (ko) | 2016-04-07 | 2023-03-13 | 더 존스 홉킨스 유니버시티 | 사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법 |
CN110402393A (zh) * | 2016-11-24 | 2019-11-01 | 休伯特保健公司 | 疾病诊断的组合物 |
AU2018327225A1 (en) * | 2017-09-06 | 2020-02-27 | Fred Hutchinson Cancer Center | Strep-tag specific chimeric receptors and uses thereof |
US11505782B2 (en) | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
DE4137333A1 (de) * | 1991-11-13 | 1993-05-19 | W Prof Dr Sebald | Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung |
US6534051B1 (en) * | 1992-11-20 | 2003-03-18 | University Of Medicine And Dentistry Of New Jersey | Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins |
AU695726B2 (en) | 1993-09-07 | 1998-08-20 | Smithkline Beecham Corporation | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
DE4423131A1 (de) * | 1994-07-01 | 1996-01-04 | Bayer Ag | Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4 |
JPH10502249A (ja) * | 1994-07-05 | 1998-03-03 | スティーノ・リサーチ・グループ・アクティーゼルスカブ | 免疫調節剤 |
CZ25697A3 (en) | 1994-07-29 | 1997-09-17 | Smithkline Beecham Plc | Novel compounds |
US5710023A (en) * | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
US6664227B1 (en) * | 1996-03-01 | 2003-12-16 | Genetics Institute, Llc | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
US20030124125A1 (en) * | 1996-04-05 | 2003-07-03 | South Alabama Medical Science Foundation | Oncofetal antigen specific T-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10 |
US6028176A (en) * | 1996-07-19 | 2000-02-22 | Bayer Corporation | High-affinity interleukin-4 muteins |
CA2309598A1 (en) * | 1997-11-10 | 1999-05-20 | Mochida Pharmaceutical Co., Ltd. | Preventives and remedies for diffuse lung disease |
JPH11312463A (ja) * | 1998-04-28 | 1999-11-09 | Hitachi Ltd | 配線基板およびそれを用いたガス放電型表示装置 |
US6896885B2 (en) * | 2000-03-31 | 2005-05-24 | Biogen Idec Inc. | Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma |
AU2001273413A1 (en) * | 2000-07-12 | 2002-01-21 | Immunex Corporation | Method for treating cancer using an interleukin- 4 antagonist |
CA2464695A1 (en) * | 2001-10-26 | 2003-05-01 | Centocor, Inc. | Il-13 mutein proteins, antibodies, compositions, methods and uses |
US20040023338A1 (en) * | 2001-10-26 | 2004-02-05 | Heavner George A. | IL-4 mutein proteins, antibodies, compositions, methods and uses |
EP1444989A1 (en) * | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
EP1824886B1 (en) * | 2004-11-17 | 2010-12-22 | Amgen Inc. | Fully human monoclonal antibodies to il-13 |
US20070122855A1 (en) * | 2005-11-28 | 2007-05-31 | Targetgen Inc. | Methods for diagnosing hepatocellular carcinoma |
US20100297110A1 (en) * | 2006-03-22 | 2010-11-25 | Apogenix Gmbh | Antibody specific for human il-4 for the treatment of cancer |
EP2049147A2 (en) * | 2006-07-06 | 2009-04-22 | Apogenix GmbH | Human il-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy |
-
2007
- 2007-06-21 RU RU2009101783/15A patent/RU2009101783A/ru not_active Application Discontinuation
- 2007-06-21 CN CNA2007800295788A patent/CN101529253A/zh active Pending
- 2007-06-21 BR BRPI0713484-3A patent/BRPI0713484A2/pt not_active IP Right Cessation
- 2007-06-21 AT AT07764767T patent/ATE520032T1/de not_active IP Right Cessation
- 2007-06-21 CA CA002656379A patent/CA2656379A1/en not_active Abandoned
- 2007-06-21 US US12/306,070 patent/US20090324616A1/en not_active Abandoned
- 2007-06-21 ES ES07764767T patent/ES2371287T3/es active Active
- 2007-06-21 AU AU2007263265A patent/AU2007263265A1/en not_active Abandoned
- 2007-06-21 DK DK07764767.5T patent/DK2041576T3/da active
- 2007-06-21 WO PCT/EP2007/005480 patent/WO2007147600A2/en active Application Filing
- 2007-06-21 EP EP07764767A patent/EP2041576B1/en active Active
- 2007-06-21 JP JP2009515770A patent/JP2010514409A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010514409A5 (ja) | ||
Yi et al. | Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors | |
Ding et al. | Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy | |
US20240102109A1 (en) | Methods for sequencing samples | |
Wang et al. | Recent studies of 5-fluorouracil resistance in pancreatic cancer | |
Giménez‐Bonafé et al. | YB‐1 is upregulated during prostate cancer tumor progression and increases P‐glycoprotein activity | |
Durães et al. | Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? | |
RU2009101783A (ru) | Дифференциальная экспрессия цитокинов il-4 и/или il-10 в злокачественной опухоли человека | |
ES2355388T3 (es) | Métodos para la detección precoz de cáncer. | |
Namløs et al. | Global gene expression profiling of human osteosarcomas reveals metastasis‐associated chemokine pattern | |
Sarshekeh et al. | Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer | |
Ji et al. | Somatic mutations and immune alternation in rectal cancer following neoadjuvant chemoradiotherapy | |
Sozucan et al. | TRP genes family expression in colorectal cancer | |
Rahim et al. | The role of interleukin-6 in malignant mesothelioma | |
Zhen et al. | Impact of HLA-E gene polymorphism on HLA-E expression in tumor cells and prognosis in patients with stage III colorectal cancer | |
Loharamtaweethong et al. | Anaplastic lymphoma kinase (ALK) translocation in paediatric malignant peritoneal mesothelioma: A case report of novel ALK‐related tumour spectrum | |
Ng Kee Kwong et al. | Expression of PD‐L1 correlates with pleomorphic morphology and histological patterns of non‐small‐cell lung carcinomas | |
Li et al. | Functional and therapeutic significance of tumor-associated macrophages in colorectal cancer | |
Goričar et al. | Extracellular vesicles: A novel tool facilitating personalized medicine and pharmacogenomics in oncology | |
Zhang et al. | Clinical significance of hmgb1 expression in human gastric cancer | |
Cybulski et al. | Cyclin A correlates with YB1, progression and resistance to chemotherapy in human epithelial ovarian cancer | |
Liu et al. | Evolving personalized therapy for castration-resistant prostate cancer | |
Tu et al. | Serum decoy receptor 3 level: a predictive marker for nodal metastasis and survival among oral cavity cancer patients | |
Ramirez-Torres et al. | Quantitative proteomic analysis of cervical cancer tissues identifies proteins associated with cancer progression | |
de Nonneville et al. | Sacituzumab govitecan in triple-negative breast cancer |